![Neffy® is first alternative to injections for severe allergic reactions, anaphylaxis](/sites/default/files/styles/400_x_202/public/2024-08/N29890_FDA%20approval%20for%20Epinephrine%20Nasal%20Spray-Blog%20%281%29.jpg?h=bf654dbc&itok=e08Sr5qz&cb=9f6d5168)
The Food and Drug Administration (FDA) has approved an epinephrine nasal spray for severe allergic reactions, the first treatment for those reactions and anaphylaxis that is not administered by injection.
Anaphylaxis is a severe, life-threatening allergic reaction that can be brought on by insect bites, foods, medications or latex. Symptoms vary but can include a swollen throat or swollen areas of the body, wheezing, chest tightness, trouble breathing, trouble swallowing, unconsciousness and more. Epinephrine is the only lifesaving treatment for anaphylaxis.
The FDA approval for neffy, developed by California-based ARS Pharmaceuticals, Inc. came Friday (Aug. 9). ARS says the approval represents the first significant innovation in the delivery of epinephrine in more than 35 years and is the first and only needle-free treatment option for patients and families living with severe allergic reactions.